Venrock Healthcare Capital Partners III, L.P., 10% Owner at Lycia Therapeutics, Inc. (LYCA), bought 25,004 shares at $25.23 ($645K) on 2026-10-28, disclosed to the SEC on 2026-10-30.
Venrock Healthcare Capital Partners III, L.P. executed a $266,681 purchase of 10,570 shares at $25.23, marking the largest insider purchase in the company's history. This significant accumulation suggests the firm views the current valuation as attractive relative to its long-term potential.
The stock is trading at $27.26, down 8.34% over the last 5 days and sitting 24.85% below its 52-week high of $36.28, indicating a pullback from recent highs.
Insider cluster momentum: This is the largest insider purchase ever recorded for Lycia Therapeutics, Inc.; track this momentum as a signal of conviction.
Valuation risk: The stock is currently trading 24.85% below its 52-week high, suggesting the market may be pricing in significant downside risk or uncertainty.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.23 | 10,570 | $267K | 41.4% |
| 2 | $25.97 | 4,430 | $115K | 17.8% |
| 3 | $26.33 | 1,000 | $26K | 4.1% |
| 4 | $26.27 | 8,804 | $231K | 35.9% |
| 5 | $26.86 | 200 | $5K | 0.8% |
| Total | $25.78 avg | 25,004 |
| $645K |
| 100% |